SAMD4A and myotonic dystrophy type 1: Increasing levels of human SAMD4A can decrease the abnormal nuclear accumulation of CUGBP1 with high steady-state levels in myoblasts from DM1 patients, and also reduce the number of inactive CUGBP1-eIF2α translational complexes.